Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists

NCT00859131 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

200

Enrollment

OTHER

Sponsor class

Conditions

End Stage Renal Disease

Interventions

DRUG: Rabbit Antithymocyte globulin
DRUG: Daclizumab

Sponsor

Medical University of South Carolina

Collaborators

[object Object]